Global Antibody Partnering Terms and Agreements 2015-2022

$3,495.00

The Global Antibody Partnering Terms and Agreements 2015 - 2022 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2022
Number of pages
1000+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2113

The Global Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

 

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb
  • Bispecific antibodies 
  • Polyclonal antibodies

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 1,900 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading Antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2015.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

 

Key benefits

 

Global Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

 

  • In-depth understanding of Antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Antibody contracts enter into by the leading 25 bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Antibody Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

 

Global Antibody Partnering Terms and Agreements 2015 to 2022 includes:     

  • Trends in Antibody dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1,900 Antibody online deal records
  • The leading Antibody deals by value since 2015
  • Most active Antibody dealmakers since 2015
  • The leading Antibody partnering resources

 

In Global Antibody Partnering Terms and Agreements 2015 to 2022, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive access to available deals and contract documents for over 1,900 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise Antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Antibody Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:

 

  • In-depth understanding of antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 1,900 actual antibody deals entered into by the world’s biopharma companies,  together with contract documents if available
  • Detailed access to actual antibody contracts enter into by the leading companies
  • Identify leading antibody deals by value since 2015
  • Identify the most active antibody dealmakers since 2015
  • Insight into the terms included in a antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in antibody dealmaking

 

2.1. Introduction
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates

 

Chapter 3 – Leading antibody deals

 

3.1. Introduction
3.2. Top antibody deals by value

 

Chapter 4 – Most active antibody dealmakers

 

4.1. Introduction
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles

 

Chapter 5 – Antibody contracts dealmaking directory

 

5.1. Introduction
5.2. Antibody contracts dealmaking directory

 

Chapter 6 – Antibody dealmaking by technology type

 

Appendices

 

Appendix 1 – Antibody deals by company A-Z

 

Appendix 2 – Antibody deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Antibody deals by deal type

 

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

 

Appendix 4 – Antibody deals by therapy area

 

Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Respiratory

 

Appendix 5 – Deal type definitions

 

Appendix 6 – Further reading on dealmaking

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

 

Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2015
Figure 3: Active antibody dealmaking activity since 2015
Figure 4: Antibody partnering by deal type since 2015
Figure 5: Antibody partnering by disease type since 2015
Figure 6: Antibody deals with a headline value
Figure 7: Antibody deals with an upfront value
Figure 8: Antibody deals with a milestone value
Figure 9: Antibody deals with a royalty rate value
Figure 10: Top antibody deals by value since 2015
Figure 11: Most active antibody dealmakers since 2015

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3B Pharmaceuticals, A*STAR Agency for Science, Technology and Research, Abbott Laboratories, Accelr8, Acella Pharmaceuticals, Achaogen, Acurx Pharmaceuticals, Advanced Life Sciences, Advanced Technology Company, Advance Trading, Advanz Pharma, Affibody, Akorn, Albert Einstein College of Medicine, Alfa Wassermann, ALK-Abello, Allecra Therapeutics, Allegis Pharmaceuticals, Allergan, Allergan (name changed from Actavis), AllerQuest, Almirall, Amerigen Pharmaceuticals, Amicogen, AmpliPhi Biosciences, AMR, Amyris, Anacor Pharmaceuticals, Anatara Lifesciences, Angelini Pharma, ANI Pharmaceuticals, AnnaMed, Antibiotic Research UK, Apotex, Appili Therapeutics, Aptalis Pharma, Aqua Pharmaceuticals, Aradigm, arGEN-X, aRigen, ARK Diagnostics, Arrevus, Artizan Biosciences, Aspen Holding, Astellas Pharma, AstraZeneca, Aurobindo Pharma, Aurospharma Company, Auspherix, Australian Research Council, Avails Medical, AvidBiotics, Aytu BioPharma, Basilea Pharmaceutica, Bayer, Biocon, BioConnections, Biomedical Advanced Research and Development Authority, bioMerieux, Biophore Pharmaceuticals, BioVersys, Boston Pharmaceuticals, Boston University, Boulos and Cooper Pharmaceuticals, Brii Biosciences, BSP Pharmaceuticals, Bugworks, Cadila Pharmaceuticals, California Institute for Biomedical Research, Cantab Anti-infectives, Cantab Biopharmaceuticals, CARB-X, Cardinal Health, Cardiome Pharma, Cempra Pharmaceutical, Centre for Drug Research and Development (CDRD), Cepheid, Checkpoint Therapeutics, Chelexa Biosciences, Cidara Therapeutics, Cipla, Citius Pharmaceuticals, Civica Rx, Cleveland Clinic, Clinigen, Colorado State University, Cook Medical, Correvio Pharma, Cosmo Pharmaceuticals, Covance, Creative Antibiotics, Crestone Pharma, CSPC Pharmaceutical Group, Cubist Pharmaceuticals, CUBRC, Cumberland Pharmaceuticals, Cumencor Pharmaceuticals, Curetis, CURx Pharmaceuticals, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, D&A Pharma, Dana-Farber Cancer Institute, Debiopharm, Decibel Therapeutics, de Duve Institute, Defence Science and Technology Laboratory, Defense Threat Reduction Agency, Deinove, Department of Defense, Department of Health and Human Services, Dermin, Diod, Dipexium Pharmaceuticals, Discuva, DKSH, Dr. Reddy's Laboratories, DSM Sinochem Pharmaceuticals, Durata Therapeutics, Eagle Pharmaceuticals, Eddingpharm, Eli Lilly, Emergent BioSolutions, Enanta Pharmaceuticals, Entasis Therapeutics, Enterome Bioscience, Ercros, Euprotec, Eurofarma, Eurofins Scientific, European Commission, European Investment Bank, European Union, Everest Medicines, Evolva, Evotec, Federal Ministry of Education and Research (BMBF), Fedora Pharmaceuticals, Ferrer International, Finorga, Flamel Technologies, Flemish agency for Innovation by Science and Technology, Florida International University, Foamix Pharmaceuticals, FOB Synthesis, Forest Healthcare, Forest Laboratories, Forge Therapeutics, Forsyth Institute, Foundation for Innovative New Diagnostics, France's General Directorate for Armaments, FSC Laboratories, Fundacion Medina, Galapagos, Galderma, GC Pharma, Genentech, Genetics Laboratory, Genzyme, Geom Therapeutics, Gilead Sciences, GlaxoSmithKline, Global Antibiotic Research and Development Partnership, GPCR Therapeutics, Grunenthal, Gyma Laboratories of America, Hackensack Meridian Health, Hainan Haiyao, Harvard Medical School, Harvard University, Helmholtz Centre for Infection Research, Helperby Therapeutics, Heraeus, Hi-Tech Pharmacal, Hikma Pharmaceuticals, Hoffmann La Roche, Hospira, Hoth Therapeutics, Hvidovre Hospital, Ichor Biologics, ID Genomics, Imaxio, InfectoPharm, Infex Therapeutics, Ingenza, Innosuisse, Innovate UK, Innovative Medicines Initiative (IMI), Inovio Pharmaceuticals, InSite Vision, Insmed Inc, Intrexon, Iroko Pharmaceuticals, Italfarmaco, Jade Therapeutics, Johns Hopkins University, Johnson & Johnson, Journey Medical, Kala Pharmaceuticals, Kinnear Pharmaceuticals, Knauer Scientific Instruments, Laboratory Corporation of America, Lawrence Livermore National Laboratory, LegoChem Biosciences, Leicester University, LEO Pharma, Leukocare, LGC, LifeArc, Liverpool School of Tropical Medicine, Luminarie, Lysando, Macrolide Pharma, Magle Chemoswed, Matinas Biopharma, McKesson, MD Anderson Cancer Center, Medicines Patent Pool Foundation, Medimetriks, MedImmune, Medivir, Meiji Seika, Melinta Therapeutics, Merck and Co, MerLion, Merus Labs International, Microbiotix, MicuRx Pharmaceuticals, Moleculin Biotech, Monash University, Motif Bio, MSD, Mylan Pharmaceuticals, Nabriva Therapeutics, NacuGen Therapeutics, NAEJA Pharmaceutical, Nanologica, nanoMR, National Eye Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, National Institute of Standards and Technology, National Institutes of Health, National Science Foundation, Nosopharm, Novalar Pharmaceuticals, NovaMedica, Novartis, Novasep, OBI Pharma, Ohio Clinical Trials Collaborative, Olon, Onset Dermatologics, Opal Therapeutics, OpGen, Oppilotech, Optimer Pharmaceuticals, Oragenics, Oricula Therpeutics, Otonomy, Oxford Drug Design, PacificGMP, Paratek Pharmaceuticals, Patheon, Pennsylvania State University, Peptilogics, Pergamum, Pernix Therapeutics, Pfizer, PharmaSwiss, Phenomenex, Pherecydes Pharma, Phico Therapeutics, Phosphagenics, Phylogica, Pieces Technologies, Polypeptide Laboratory, Polyphor, Pragma Pharmaceuticals, Premier Inc, Prev AbR, Primetime Life Sciences, Procarta Biosystems, Prokaryotics, Proteo Biotech, Q-linea AB, Qpex Biopharma, Quintiles, Quotient Bioresearch, QureTech Bio, R-Pharm, Rafarma Pharmaceuticals, Raptor Pharmaceutical, RaQualia Pharma, Rasna Therapeutics, Recce Pharmaceuticals, Recida Therapeutics, RedHill Biopharma, Rempex Pharmaceuticals, Research Council of Norway, RMX Biopharma, Roche, RRD International, Rutgers University, Salix Pharmaceuticals, Sandoz, Sanofi, Saptalis Pharmaceuticals, Savara Pharma, Sciex, Scripps Research Institute, Selcia, SeLux Diagnostics, Senju Pharmaceutical, Sequella, Shanghai Haini Pharmaceutical, Shanghai Knowshine, Shanghai MengKe Pharmaceuticals, Shanghai Zhangjiang Biomedical Industry Venture Capital, Shanglian Biochemical Medicine, Shenzhen China Resources Gosun Pharmaceutical, Shionogi, Shire Pharmaceuticals, SIFI (Societa Industria Farmaceutica Italiana), Sigma-Tau, Sinovant Sciences, SinSa Labs, SINTEF, SI Pharmaceuticals, Specialised Therapeutics, SpeeDx, Spero Therapeutics, Statens Serum Institute, Stiefel Laboratories, Stratos Group, Strides Arcolab, Strox Biopharmaceuticals, Summit Therapeutics, Suzhou NeuPharma, Swedish Orphan Biovitrum, Swedish University of Agricultural Sciences, Swixx Biopharma, Synthetic Biologics, Tabuk Pharmaceutical, Taiba, TaiGen Biotechnology, TB Alliance, TCG Life Sciences, Technology Strategy Board (UK), Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Texas A&M University, The Medicines Company, Theravance, Theravance Biopharma, The Regents of the University of California, Thermo Fisher Scientific, Tiziana Life Sciences, TLC Medical, Tongli Pharmaceuticals, Toyama Chemical, TranScrip, TransPerfect Trial Interactive, Trellis Bioscience, Tripex Pharmaceuticals, Trius Therapeutics, University of Bergen, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Florida, University of Florida Research Foundation, University of Liverpool, University of Melbourne, University of New South Wales, University of North Carolina, University of Pennsylvania, University of Queensland, University of Sherbrooke, University of Technology Sydney, University of Washington, University of Zurich, US Army Medical Research Institute of Infectious Diseases, UTILITY Therapeutics, UT Southwestern Medical Center, Valeant Pharmaceuticals, Vansen Pharma, VenatoRx, Venus Remedies, Verity Pharmaceuticals, Vernalis, Vertex Pharmaceuticals, Vinnova, Viropharma, Walter Reed Army Institute of Research, Warner Chilcott, Warp Drive Bio, Wellcome Trust, Wistar Institute, Wockhardt, Wuxi Apptec Laboratory Services, X-Biotix Therapeutics, X-chem, XBiotech, Xellia Pharmaceuticals, Yissum Research Development, ZAI Laboratory, Zhejiang Medicine, Zydus Cadila

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!